Brokerages forecast that Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) will report ($0.17) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Four analysts have issued estimates for Ironwood Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.06) and the lowest estimate coming in at ($0.35). Ironwood Pharmaceuticals reported earnings per share of ($0.14) during the same quarter last year, which would indicate a negative year-over-year growth rate of 21.4%. The company is expected to issue its next quarterly earnings report before the market opens on Wednesday, February 13th.
According to Zacks, analysts expect that Ironwood Pharmaceuticals will report full-year earnings of ($1.06) per share for the current year, with EPS estimates ranging from ($1.09) to ($1.02). For the next year, analysts anticipate that the business will report earnings of $0.23 per share, with EPS estimates ranging from ($0.12) to $0.72. Zacks’ earnings per share averages are an average based on a survey of analysts that that provide coverage for Ironwood Pharmaceuticals.
Several brokerages recently issued reports on IRWD. Zacks Investment Research raised Ironwood Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, January 28th. BidaskClub raised Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, January 31st. HC Wainwright set a $13.00 target price on Ironwood Pharmaceuticals and gave the company a “sell” rating in a research report on Wednesday, October 31st. ValuEngine cut Ironwood Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, December 12th. Finally, Wood & Company reaffirmed a “buy” rating on shares of Ironwood Pharmaceuticals in a research report on Thursday, January 31st. Two analysts have rated the stock with a sell rating, seven have given a hold rating and six have assigned a buy rating to the company. Ironwood Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $17.28.
In other Ironwood Pharmaceuticals news, CEO Peter M. Hecht sold 30,000 shares of the business’s stock in a transaction on Wednesday, January 23rd. The stock was sold at an average price of $12.66, for a total value of $379,800.00. Following the sale, the chief executive officer now directly owns 4,726,917 shares in the company, valued at $59,842,769.22. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Peter M. Hecht sold 89,551 shares of the business’s stock in a transaction on Friday, January 25th. The shares were sold at an average price of $12.53, for a total value of $1,122,074.03. Following the completion of the sale, the chief executive officer now owns 4,726,917 shares in the company, valued at $59,228,270.01. The disclosure for this sale can be found here. Insiders have sold 121,551 shares of company stock worth $1,526,814 over the last quarter. 7.63% of the stock is currently owned by corporate insiders.
Several institutional investors and hedge funds have recently modified their holdings of IRWD. CWM LLC bought a new stake in shares of Ironwood Pharmaceuticals in the fourth quarter valued at $31,000. First Manhattan Co. bought a new stake in shares of Ironwood Pharmaceuticals in the fourth quarter valued at $133,000. Bank of Montreal Can raised its stake in shares of Ironwood Pharmaceuticals by 426.9% in the fourth quarter. Bank of Montreal Can now owns 16,846 shares of the biotechnology company’s stock valued at $175,000 after buying an additional 13,649 shares during the period. Pacer Advisors Inc. bought a new stake in shares of Ironwood Pharmaceuticals in the third quarter valued at $177,000. Finally, Campbell & CO Investment Adviser LLC bought a new stake in shares of Ironwood Pharmaceuticals in the third quarter valued at $249,000. Hedge funds and other institutional investors own 93.85% of the company’s stock.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals, Inc, a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout in adults under the ZURAMPIC and DUZALLO names.
Further Reading: What is a back-end load?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.